ストックスクリーナーアプリを入手
1.57
0.63%
-0.01
アフターアワーズ：
1.57
前日終値:
$1.58
開ける：
$1.57
24時間の取引高:
951.37K
Relative Volume:
0.50
時価総額：
$168.32M
収益：
$11.16M
当期純損益:
$-148.13M
株価収益率:
-0.9884
EPS:
-1.5885
ネットキャッシュフロー:
$-112.35M
1週間 パフォーマンス:
-5.42%
1か月 パフォーマンス:
-4.85%
6か月 パフォーマンス:
+1.29%
1年 パフォーマンス:
-20.71%
1日の値動き範囲:
$1.55
$1.59
1週間の範囲:
$1.52
$1.72
52週間の値動き範囲:
$1.38
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
名前
Caribou Biosciences Inc
セクター
電話
510-982-6030
住所
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.57 | 169.39M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 開始されました | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 開始されました | Evercore ISI | Outperform |
| 2023-07-11 | 開始されました | Truist | Buy |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-12-01 | 開始されました | Oppenheimer | Outperform |
| 2021-11-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-15 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-17 | 開始されました | BofA Securities | Buy |
| 2021-08-17 | 開始されました | Citigroup | Neutral |
| 2021-08-17 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Caribou Biosciences Inc (CRBU) 最新ニュース
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $5.00 by Analysts at Bank of America - MarketBeat
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside - TradingView
Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Caribou Biosciences Q2 EPS beats estimate, sales miss - scanx.trade
Form 8K Caribou Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Caribou Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CARIBOU BIOSCIENCES ($CRBU) Releases Q2 2026 Earnings - Quiver Quantitative
Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss - TradingView
Caribou Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients - Stock Titan
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Caribou Biosciences, Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Number of shareholders of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences, Inc. $CRBU Stock Holdings Raised by Renaissance Technologies LLC - MarketBeat
Spotlight On Promising Penny Stocks For August 2026 - Sahm
Caribou Biosciences (CRBU) to Announce Earnings on Wednesday - MarketBeat
CRBU Q2'26 Earnings: revenue estimate is 2.28M USD - TradingView
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - TMX Newsfile
Caribou Biosciences (CRBU) Pulls Back to $1.46 as Clinical-Stage Biotech Faces Selling PressureBox Spread - dars.gov.et
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that. - pharmavoice.com
CRBU|Caribou Biosciences Inc|Price:1.650|Chg%:+0.010 - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.585|Chg%:+0.015 - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Cash Flow - TradingKey
BlackRock (NYSE: BLK) reports 7.2% beneficial stake in Caribou Biosciences (CRBU) - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Balance Sheet - TradingKey
Enterprise value to EBITDA forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Income Statement - TradingKey
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences, Inc. Revenue Breakdown – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.570|Chg%:-0.060 - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Price to earnings forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences (NASDAQ:CRBU) Stock Price Up 1.9%Time to Buy? - MarketBeat
Caribou Biosciences secures e-poster spot for ANTLER abstract at PPLC 2026 - Traders Union
Caribou Biosciences Inc (CRBU) Institutional Confidence - TradingKey
Are medical stocks lagging Caribou Biosciences (CRBU) this year? - MSN
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - Yahoo Finance
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, - GuruFocus
Caribou Biosciences stock holds focus on CRISPR therapies - ad-hoc-news.de
Discover 3 Promising Penny Stocks With Market Caps Above $30M - simplywall.st
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com
Caribou Biosciences Inc (CRBU) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):